Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Resource Type
Article
Authors
Tewari, Krishnansu S ; Sill, Michael W ; Penson, Richard T ; Huang, Helen ; Ramondetta, Lois M ; Landrum, Lisa M ; Oaknin, Ana ; Reid, Thomas J ; Leitao, Mario M ; Michael, Helen E ; DiSaia, Philip J ; Copeland, Larry J ; Creasman, William T ; Stehman, Frederick B ; Brady, Mark F ; Burger, Robert A ; Thigpen, J Tate ; Birrer, Michael J ; Waggoner, Steven E ; Moore, David H ; Look, Katherine Y ; Koh, Wui-Jin ; Monk, Bradley J
Source
In The Lancet 7-13 October 2017 390(10103):1654-1663
Subject
Primary Research Articles
Language
ISSN
0140-6736